Tidutamab (XmAb18087)

Entered into a Phase 1 clinical trial for the treatment of neuroendocrine tumors (NET) and gastrointestinal stromal tumors (GIST) in February 2018.

Tidutamab (XmAb18087), is a bispecific antibody that engages the immune system against tumors by binding to somatostatin receptor 2 (SSTR2) and CD3. An XmAb Bispecific Fc domain serves as the scaffold for these two antigen binding domains and confers long circulating half-life, stability and ease of manufacture on tidutamab.

In preclinical studies, tidutamab has shown potent killing of human tumor cell lines in vitro and in vivo, and the stimulation of target-dependent T-cell activation.